The aim of the study was to evaluate the pattern of utilization of systemic drugs used in the management of adverse drug reactions (ADRs) leading to hospitalization. A prospective pharmacovigilance study was carried out among patients admitted to the Clinic of Dermatology and Venereology in Stara Zagora (July 1999 -June 2009). ADRs were classified by type, severity and causality. Casecausality was scored according to Naranjo et al. (1981) . Drug utilization was measured in defined daily doses (DDDs) per 100 hospital bed days. A total of 144 cutaneous ADRs, predominantly "type B" were the reason for hospitalization. Highest utilization for the management of ADRs was found for the drug groups "Blood and blood forming organs" (406.08 DDDs/100 bed days) and "Respiratory system" (111.15 DDDs/100 bed days). The use of DDD for measuring drug utilization reveals the importance of drug-induced exacerbations of chronic skin diseases like psoriasis which were associated with significant utilization of drugs belonging to the group "Blood and blood forming organs". Considering the low preventability of "type B" ADRs, our findings suggest that potential reduction of drug-related hospitalizations may be achieved through the rational use of drugs in patients with comorbidities.
Introduction
An adverse drug reaction (ADR) is any noxious, unintended, and undesired effect of a drug that occurs at doses used for prophylaxis, diagnosis, or therapy or for modification of physiological function [1] . Morbidity and mortality associated with ADRs have been recognized as a significant public health and economic problem in the last decades. ADRs may lead to transitory or permanent organ damage, including death. ADRs are estimated to be between 4th and 6th leading cause of death among hospitalized patients in the USA according to a metaanalysis of 39 prospective studies over a period of 32 years [2] . A recent prospective study on 18 820 patients from the UK showed that 6.5% of hospital admissions were related to ADRs [3] .
Cutaneous ADRs are characterized by high frequency and variable clinical presentation. The difficulties in identifying drugs as etiologic agents, and the severity of cutaneous drug reactions are the main reasons for admission to hospital of patients with these ADRs. There are single studies addressing the treatment of ADRs. The withdrawal of the culprit drug is the mainstay of treatment of an adverse reaction to drugs but most cutaneous ADRs are immunological reactions usually with a protracted course and necessitate additional therapeutic modalities as compared to dose-dependent ADRs.
The aim of the present study is to evaluate the pattern of utilization of systemic drugs used in the management of adverse drug reactions leading to hospitalization in a dermatology department.
Material and Methods
The investigation is a part of a prospective pharmacovigilance study carried out among patients admitted to the Clinic of Dermatology and Venereology in Stara Zagora (July 1999 -June 2009). Patients with readmissions to the Clinic within two consecutive months were excluded. For patients with suspected ADRs data were entered in a structured form, containing information on demographic characteristics, primary diagnosis, concomitant diseases, history of previous ADRs and drug history covering the last three months preceding hospitalization (dosage regimen, route of administration and duration of therapy), clinical description of the adverse event (onset, course, outcome, systemic and topical treatment), laboratory tests, reviews of consultants, a complete list of medications administered during hospitalization (dosage regimen, time of start of therapy and time of withdrawal) and the drugs incriminated to induce ADRs. A team consisting of dermatologists and a pharmacologist reviewed data. ADRs were defined according to WHO [1] . Drug-induced exacerbations of preexisting dermatoses were also included.
ADR classification
Criteria for ADR classification included clinical presentation, reaction type, severity and causality. ADRs were classified by their clinical manifestation using WHO-ART Adverse Reaction Terminology (The Uppsala Monitoring Centre [http://www.umc-products. com/graphics/3149.pdf ]) and by type as "type A" and "type B" reactions [4] . "Type A" reactions are dose-related and predictable reactions resulting from an exaggerated pharmacological action of the drug. "Type B" reactions are upredictable reactions unrelated to dose, that are not to be expected from the known pharmacological properties of the drug.
Regarding severity (Table 1) , ADRs were assessed as "severe" (life-threatening or serious condition with significant organ dysfunction), "moderate" (fair condition, transitory organ dysfunction) and "mild" (good condition with minor or no organ dysfunction). In cases with skin and mucosal involvement morphological criteria based on the definitions of severe skin reactions of BraunFalco et al. [5] were also applied.
The causal relationship between the drug and the adverse reaction was scored as "definite", "probable", "possible" and "doubtful" following the method of Naranjo et al. [6] . 
ASA -acetylsalicylic acid; AMX -amoxicillin; AMP -aminophenazon; CO-TM -co-trimoxazole; CL -clavulanic acid; CDU -combined drug use
depending on the sample size. Because the study values were not normally distributed, the results were presented as median and interquartile range (25th-75th percentile). The non-parametric Mann-Whitney U test was used to determine between-group differences. A value of p<0.05 was considered statistically significant. Analyses were performed using SPSS for Windows version 9.0.
Results
During the ten-year study period 2701 hospital admissions were analyzed and 286 ADRs were identified. Among these a total of 144 cutaneous ADRs were the reason for hospitalization to the Clinic of Dermatology. They comprised 5.3% of all admissions to the Clinic and 50.3% of all detected ADRs. The demographic characteristics of patients with ADRs included: age range was 6-84 years, median 56.50 (interquartile range 39.25-68.75); elderly patients (65 years or older) were 44 (30.6%) and female/male ratio was 2.13:1. History of a previous drug reaction was found in 31 (21.5 %) patients.
ADR characteristics
Cutaneous ADRs leading to hospital admission presented with a variety of clinical manifestations, the prevalent clinical patterns being urticarial and exanthematous ( reactions. Regarding imputability 105 (72.9%) ADRs were scored as "possible", 36 (25%) as "probable", 2 (1.4%) were assessed as "doubtful" and only one ADR (0.7%) as "definite". The distribution of ADRs according to therapeutic groups ( Figure 1) shows a high incidence of ADRs due to systemic antiinfectives (group J), drugs affecting cardiovascular system (group C) and combined drug use. Cases with polypharmacy (25 cases) were evaluated mainly as "possible".
ADRs leading to hospitalization resulted in 1480 hospital bed days. The mean length of hospitalization was 8 days (interquartile range 7-12). ADRs "type A" were associated with significantly more prolonged hospitalization (p=0.001) with a median of 10.5 hospital bed days (interquartile range 8.7-17) than "type B" ADRs (median 7; interquartile range 7-11).
ADR treatment
The eliciting drug was withdrawn in all cases. Systemic therapy was applied in 126 cases (87.5% of ADRs). Drug class most commonly used was H 1 Topical therapy was applied in 120 cases (83.3%). It consisted of emollients, topical corticosteroids or keratolytics. Topical therapy was the only treatment in 18 cases (12.5%). In the majority of the cases (102) topical treatment supplemented systemic therapy. Cases with drug-induced exacerbation of psoriasis were managed with vitamins, emollients and selective ultraviolet phototherapy.
Drug groups with highest utilization for the management of ADRs (Table 4) included "Blood and blood forming organs" presented by B03 Antianemic preparations (406,08 DDDs per 100 bed days) and "Respiratory system" presented by R06 Antihistamines for systemic use (111,15 DDDs per 100 bed days). Antianemic preparations included vitamin B 12 and folic acid and were used for the management of drugexacerbated psoriasis vulgaris. The ATC group "R06 Antihistamines for systemic use" corresponds to the 
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Chi-square for trend=0,00;P=0,99
A -Alimentary tract and metabolism; C -Cardiovascular system; D -Dermatologicals; G -Genito-urinary system and sex hormones; H -Systemic hormonal preparations, excl. sex hormones and insulins; J -Antiinfectives for systemic use; L -Antineoplastic and immunomodulating agents; N -Nervous system; R -Respiratory system; Comb -combined drug use
pharmacological class "H 1 -RA". Overall utilization of first generation antihistamines was estimated to be equivalent to 67.47 DDDs per 100 hospital bed days and of second-generation antihistamines to 43.72 DDDs per 100 hospital bed days. No significant increase in the proportion of second-generation antihistamines used to treat ADRs was established in the course of the study p=0,99 ( Figure 2) . Loratadine was the antihistamine preparation with the highest number of DDDs per 100 hospital bed days, followed by two antihistamines belonging to the first generation, cyproheptadine and clemastin ( Figure 3 ). Corticosteroids (parenteral methylprednisolone, oral methylprednisolone and prednisolone) from the ATC group H "Systemic hormonal preparations" were used as antiallergic medication.
Drugs belonging to group A "Alimentary tract and metabolism" used for the treatment of ADRs were: H 2 -RA in combination with corticosteroids for the purpose of suppressing their adverse effects, magnesium sulfate used as laxative in cases of acute urticaria and ascorbic acid used as vasoprotective agent.
Single DDDs of drugs from the groups "Nervous system" (hydroxizine, opioid-and non-opioid analgesics), "General antiinfectives for systemic use" (aciclovir) and "Antineoplastic and immunomodulating agents" (azathioprine) were also applied.
Discussion
ADRs leading to hospitalization constituted 5.3% of all hospitalizations to the Clinic of Dermatology and Venereology. This finding is consistent with data from similar studies in hospitalized patients. Meta-analyses show that 2.4-6.2% from all hospitalizations are due to ADRs [7, 8] . A recent systematic review of prospective observational studies using the WHO ADR definition ascertains an overall median prevalence rate of hospital admission associated with ADRs 5.3% [9] . However, we found only one study performed in a dermatology clinic that addressed drug-related hospitalizations. Jenerowicz et al. report a proportion of 1% of all hospitalizations to the Department of Dermatology being attributed to ADRs [10] . The authors explain this low frequency with the lack of emergency services and only planned admissions to that department.
The prevalent type of ADRs in our study were categorized as "type B" ADRs which are not dependent on the drug dosage applied, and are considered to be mainly of allergic nature. They manifested with variable clinical picture the most common being urticaria with or without Quincke`s edema and exanthematous reaction in concordance with results from similar investigations [10] . Because it was not possible at the time of hospitalization to confirm the immunological or nonimmunological mechanism of the reactions all patients with "type B" ADRs were treated for an allergic disease. Most important in the management of "type B" reactions was the withdrawal of the offending drug. If more than one drug was suspected in cases with polypharmacy all preparations were withdrawn.
The causal relationship between the cutaneous ADR and the drug was evaluated as "possible" in the majority (72.9%) of the cases. This can be explained by the fact that various agents different from drugs may induce cutaneous reaction patterns. It is well known for example that exanthematous reaction, often designated in literature as "maculopapular rash", may be associated with various viral infections [5] . Due to polypharmacy in 17.4% of the studied patients the ADR received a lower level of probability by the Naranjo scale, and this finding is in line with the results of Fiszenson et al., who confirm the difficulties to attest the imputability of a drug especially when there is concomitant use of multiple drugs [11] . The high proportion of "type B" reactions may also be the reason for this considerably low level of probability of drug causation because the algorithms used for establishing drug causality are adjusted for pharmacologically dependent ADRs [12] and cannot replace allergy testing in hypersensitivity reactions [13] . Drug provocation tests were not performed for ethical reasons and this resulted in a rather low proportion of "definite" ADRs.
Irrespective of the level of probability of drug causation all patients with ADRs leading to hospitalization were given systemic or local treatment or both. Treatment was dependent on the severity of the ADR: the presence of life-threatening symptoms like Quincke`s edema, widespread urticaria and angioedema, DRESS syndrome and AGEP required the administration of parenteral corticosteroids; generalized exanthematous reactions were usually treated with combinations of sedating and non-sedating antihistamine preparations. Various combined therapy regimens including antihistamines, vasoprotectives, vitamins were used.
When referring to the drug class as a proportion, antihistamines (H 1 -RA) were the drug class most commonly used. This finding is consistent with the results reported by Mishra et al. [14] , the only study we found that evaluated the treatment of cutaneous ADRs. Overall first generation antihistamines were utilized more than second-generation antihistamines although loratadine was the drug with highest DDDs per hospital bed days. The first-and second-generation antihistamines are similar in efficacy and differ mainly in their safety profiles. The advantage of secondgeneration antihistamines to cause less sedation is of no particular importance when treating acute allergic reactions in a hospital setting. Effective treatment of severe pruritic dermatoses is usually achieved namely with the use of sedating antihistamines. Moreover the available antihistamine preparation for parenteral use chloropyramine belongs to the first-generation antihistamines. Despite the marketing of new high-cost second-generation antihistamines in recent years their proportion of all antihistamine preparations used for the treatment of ADRs did not increase in the course of this study.
However, when measuring drug utilization by DDDs another drug group was revealed as first ranking in the treatment of ADRs, i.e. "Blood and blood forming organs". This drug group is used for the management of exacerbations of psoriasis vulgaris including druginduced exacerbations, which were evaluated as "type A" reactions. Although there are still gaps in the basic understanding of psoriasis, it is now accepted that psoriasis is a chronic, immune-mediated inflammatory disease [15] , which appears to arise through multiple genetic risk factors interacting with each other and with environmental factors such as β-haemolytic streptococcal infection, stress, and drugs [16] . Drug intake may result in exacerbation of pre-existing psoriasis or induction of the disease. In our series of patients beta-blockers, angiotensin-converting enzyme (ACE)-inhibitors and non-steroidal anti-inflammatory drugs (NSAIDs) all of which are supposed to interfere with pathogenic mechanisms of the disease were the culprit drugs. Some authors define 3 categories of drugs according to their causal relationship to the development of psoriasis: 1) drugs with undoubted causal relationship, 2) drugs with considerable but insufficient data supporting induction or aggravation of psoriasis and 3) drugs occasionally reported to be associated with induction or aggravation of psoriasis [17] . This classification lists beta-blockers as pertaining to the first group, and ACE-inhibitors to the second. Patients with psoriasis have an increased morbidity and mortality from cardiovascular events [18] , so the use of these classes of drugs in psoriatic patients with comorbidities is often a necessity. Although a recent large population-based case-control analysis did not support the proposition that use of beta-blockers, ACEinhibitors, angiotensin II antagonists, calcium channel blockers, diuretics and clonidine is associated with an increased risk of psoriasis the possibility that some of these agents may cause worsening or exacerbation of psoriasis cannot be excluded [19] . Beta-blockers are supposed to worsen psoriasis by decreasing epidermal cAMP thus increasing epidermal cell turn over [20] . ACE inhibitors may aggravate psoriasis through substance P, which is degraded by ACE [21] . The role of eicosanoids in psoriasis remains unclear although it is known that the levels of arachidonic acid and leucotriene B 4 are increased in lesional skin so it is presumed that NSAIDs worsen psoriasis through the blockade of cyclooxygenase pathway [22] . Due to a probable link between exacerbations of psoriasis and use of beta-blockers and ACE-inhibitors for concomitant cardiovascular diseases these cases were considered as ADRs, which necessitated a careful transition to new cardiovascular treatment regimens following relevant specialized consultations. Many therapeutic options are available for patients with psoriasis but except for a few recent additions to the armamentarium all treatments are empirical [23] . Vitamin B 12 may influence psoriasis due to its role in nucleic acid synthesis. A number of studies have reported decreased plasma levels of cyancobalamin and folate in psoriatic patients, perhaps due to their increased consumption in the skin during the rapid epidermal cell turn over [24, 25] . Vitamin B 12 and folic acid were used in high daily doses and consequently "Blood and blood forming organs" appeared as the drug group with the highest number of DDDs used for the treatment of ADRs. It is notable, however, that these cases assessed as "type A" ADRs were associated with a longer duration of hospitalization as compared to "type B" ADRs.
A wide variety of systemic drugs were used for the management of ADRs leading to hospitalization in the Clinic of Dermatology and Venereology. In this patient population the use of DDD for measuring drug utilization revealed the importance of drug-induced exacerbations of chronic skin diseases like psoriasis which were associated with significant utilization of drugs belonging to the ATC group "Blood and blood forming organs" although the prevalent ADRs were evaluated as "type B". Since allergic reactions are generally considered unpreventable, these findings suggest that potential reduction of drug-related hospitalizations to specialized dermatology departments may be achieved through the rational use of drugs in patients with comorbidities. Drugs known to induce exacerbations of chronic multifactorial disorders like psoriasis should be avoided by physicians when treating concomitant diseases in psoriatic patients.
